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Comparative analysis of 1152 African-American and
European-American men with prostate cancer
identiﬁes distinct genomic and immunological
differences
Walter Rayford1,17, Alp Tuna Beksac 2,17, Jordan Alger3, Mohammed Alshalalfa 4, Mohsen Ahmed2,
Irtaza Khan2, Ugo G. Falagario 2, Yang Liu5, Elai Davicioni5, Daniel E. Spratt6, Edward M. Schaeffer 7,
Felix Y. Feng 4, Brandon Mahal8, Paul L. Nguyen8, Robert B. Den9, Mark D. Greenberger1, Randy Bradley10,
Justin M. Watson11, Matthew Beamer3, Lambros Stamatakis3, Darrell J. Carmen12, Shivanshu Awasthi 13,
Jonathan Hwang3, Rachel Weil2, Harri Merisaari14, Nihal Mohamed2, Leslie A. Deane15, Dimple Chakravarty 2,
Kamlesh K. Yadav16, Kosj Yamoah 13, Sujit S. Nair 2 & Ashutosh K. Tewari 2 ✉

Racial disparities in prostate cancer have not been well characterized on a genomic level.
Here we show the results of a multi-institutional retrospective analysis of 1,152 patients (596
African-American men (AAM) and 556 European-American men (EAM)) who underwent
radical prostatectomy. Comparative analyses between the race groups were conducted at the
clinical, genomic, pathway, molecular subtype, and prognostic levels. The EAM group had
increased ERG (P < 0.001) and ETS (P = 0.02) expression, decreased SPINK1 expression (P <
0.001), and basal-like (P < 0.001) molecular subtypes. After adjusting for confounders, the
AAM group was associated with higher expression of CRYBB2, GSTM3, and inﬂammation
genes (IL33, IFNG, CCL4, CD3, ICOSLG), and lower expression of mismatch repair genes
(MSH2, MSH6) (p < 0.001 for all). At the pathway level, the AAM group had higher
expression of genes sets related to the immune response, apoptosis, hypoxia, and reactive
oxygen species. EAM group was associated with higher levels of fatty acid metabolism, DNA
repair, and WNT/beta-catenin signaling. Based on cell lines data, AAM were predicted to
have higher potential response to DNA damage. In conclusion, biological characteristics of
prostate tumor were substantially different in AAM when compared to EAM.
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rostate cancer (PCa) is the most common solid organ
malignancy in men, with 174,650 new diagnoses and 31,620
deaths expected in 2019 in the United States alone. Signiﬁcant
racial disparities exist in PCa outcomes, with African-American
men (AAM) experiencing a higher incidence (186.8 vs. 107.0
per 100,000) and mortality rate (40.8 vs. 18.2 per 100,000) than
European-American men (EAM)1.
Although previous studies have shown that multiple factors
including, cultural, socioeconomic, psychosocial, and healthcare
access disproportionately inﬂuence higher cancer burden and
consequently poor disease outcomes in AAM2,3, our knowledge
of the extent to which tumor biology contributes to the reported
level of disparities is limited. In addition, the lack of a systematic
approach to characterize the inherent differences in tumor biology in AAM precludes the detection of molecular events that are
enriched in this population4–6.
Effective prognosis and personalized treatment regimens for
PCa require identifying tumor-speciﬁc genomic factors and
events and discovering disease-associated mechanisms. Although
previous studies have demonstrated the existence of genomic
differences between AAM and EAM men, the underlying
mechanisms driving poor survival in AAM patients are not
completely understood7. A number of mechanisms have been
attributed to race disparities in PCa, including varying molecular
subtypes, anatomic tumor location, dysregulation of oncogenic
pathways, and the tumor microenvironment4,8–10. To unravel
race-speciﬁc unique molecular pathways implicated in PCa, we
leveraged a multi-institutional database and analyzed genomic
differences between AAM and EAM.

Results
Baseline characteristics. Clinico-pathologic characteristics of the
study cohort are summarized in Table 1. Importantly, compared
to EAM, AAM presented with signiﬁcantly higher pretreatment
prostate-speciﬁc antigen (PSA) levels (7.9 vs. 6.5 ng/ml, P < 0.001).
AAM also had higher combined pathologic T3b and 4 stage
(17.4% vs. 11.3%, P = 0.001) and had higher post-radical prostatectomy (RP) cancer of the prostate risk assessment postsurgical
(CAPRA-S) scores (14.9% vs. 9.7%, P < 0.001). Finally, AAM
also had higher genomic risk of metastasis compared to EAM
(Decipher high-risk group 38.2 vs. 33.2%, P = 0.04).
Prognostic implications of race. To further study prognostic
biomarkers in both races, we used 20 prognostic gene expression
signatures previously reported to be associated with the worst
outcome in PCa11. Overall, we established that AAM and EAM
segregated well into prognostically variable groups (Fig. 1a).
Furthermore, we found that in comparison across the two groups,
Decipher and the average genomic-risk (AGR) score (mean of
19 signatures excluding Decipher) were strongly associated with
grade groups (GGs) (P < 0.001) (Fig. 1b, c). GG4/5 AAM and
EAM had higher Decipher scores compared to patients with
GG1/2 and GG3. Interestingly, Decipher scores were higher in
AAM only in the GG1/2 group (P < 0.001) but not in other
groups (Fig. 1b). However, the AGR score was higher in EAM
patients with GG4/5 (P = 0.001) but was not different in the
remaining groups (Fig. 1c). These ﬁndings suggest that racial
disparities are greatest in the very low and very high-GGs.

Table 1 Baseline characteristics.
P value

Variable

All

AAM

Number of patients
Age at surgery, mean (IQR)
Preoperative PSA, median (IQR)
RP grade group, n (%)
1
2
3
4
5
pT stage, n (%)
T2
T3a
T3b
T4
pN stage, n (%)
N1
N0
CAPRA-S riska
Low
Intermediate
High
Decipher score, median (IQR)
Decipher group, n (%)
Low
Average
High

1152
63.8 (58, 68)
7 (5, 11)

596
63.3 (58, 67.7)
7.9 (5.6, 12)

53
639
281
79
100

(4.6)
(55.5)
(24.4)
(6.9)
(8.7)

35
333
131
49
48

(5.9)
(55.9)
(22)
(8.2)
(8.1)

18
306
150
30
52

(3.2)
(55)
(27)
(5.4)
(9.4)

0.024

645
274
149
18

(56\)
(23.7)
(12.9)
(1.5)

322
130
88
16

(54)
(21.8)
(14.7)
(2.7)

323
144
61
2

(58)
(26)
(11)
(0.3)

0.001

20 (3.6)
24 (4.3)

>0.999

41 (3.6%)
51 (4.4%)
208
287
143
0.52

(32.6)
(45)
(32.4)
(0.36, 0.66)

455 (39.5)
184 (15.9)
413 (35.8)

21 (3.5)
27 (4.5)
62
126
89
0.54

(22.4)
(45.5)
(32.1)
(0.38, 0.68)

215 (36)
153 (25.8)
228 (38.2)

EAM
556
64 (58, 68.7)
6.5 (4.8, 10)

146
161
54
0.50

(40.4)
(44.6)
(15)
(0.34, 0.65)

240 (43.2)
131 (23.5)
185 (33.2)

0.083
<0.001

<0.001

0.14
0.04

AAM African-American men, EAM European-American men, CAPRA-S cancer of the prostate risk assessment postsurgical, IQR interquartile range, PSA prostate-speciﬁc antigen, RP radical
prostatectomy.
Bold values indicate statistical signiﬁcance p < 0.05.
aMissing data.

2

COMMUNICATIONS BIOLOGY | (2021)4:670 | https://doi.org/10.1038/s42003-021-02140-y | www.nature.com/commsbio

COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-021-02140-y

ARTICLE

Fig. 1 Comparison of genomic-risk signatures and their grade group associations in AAM and EAM. a Prognostic differences in AAM vs. EAM. 20
prognostic signatures show similar trends in both groups. Overall, both Decipher (b) and average genomic-risk scores (c) positively correlate with grade
groups in both races. b Decipher is higher in AAM with low grades but not different in high-grade tumors. c In contrast, average genomic risk is lower in the
AAM with high-grade tumors. AAM African-American men, EAM European-American men. Error bars represent the 95% conﬁdence interval.

Molecular basis of racial disparities: genomic differences in
EAM and AAM. To understand the molecular underpinnings of
racial disparities in PCa, we analyzed molecular subtypes of PCa
within EAM and AAM groups based on the proportion of patients
associated with ERG status and PAM50 subtypes, as previously
deﬁned12. Our ﬁndings demonstrate that AAM showed increased
association with SPINK1 expression (22% vs. 10%), EAM patients
had higher ERG expression (41% vs. 23%) (Supplementary Fig. 1,
top). In line with previous studies showing that the basal-like
PAM50 subtype is associated with aggressive phenotype, we
observed AAM tumors to be strongly associated with this subtype
(42% vs. 35%) when compared to EAM tumors (Supplementary
Fig. 1, bottom).
Genome-wide differential expression between EAM and AAM.
Multivariable logistic regression was used to identify genes that
were differentially expressed between the two groups after
adjusting for pathological variables (GG, clinical T stage, lymph
node involvement), and multiple testing. Using a false discovery
rates (FDR) threshold of 1e−5, we found 4585 genes to be differentially expressed, with 778 overexpressed in the AAM group
(Supplementary Fig. 2, Supplementary Data 2). The top differentially expressed genes in our cohort and TCGA are shown in
Fig. 2a. Performing differential expression analysis using a Wilcoxon test in the TCGA-PCa cohort (37 AAM, 233 EAM), we
found 35 genes (out of 560 genes upregulated in AAM in TCGA
prostate) in common with the 778 upregulated genes in our
cohort, and 295 genes (out of 646 genes with signiﬁcant lower
expression in AAM in TCGA prostate) in common with the 3807

genes downregulated in AAM in our cohort. We believe the small
overlap between the two cohorts is ﬁrst due to platform difference
(RNA-seq vs. microarray) and difference in AAM sample size
(37 in TCGA vs. 596 in our cohort).
CRYBB2 is one of the most upregulated genes in the AAM
group in both the TCGA prostate cohort and our cohort. Other
genes, including GSTM3, SNX31, and TENM1, were among the
top genes upregulated in AAM in both cohorts (Fig. 2b). CRYBB2
and PSPH had been previously reported to be overexpressed in
breast cancer samples13 and colorectal cancer samples from AAM
patients14. This suggests that these genes are overexpressed
in AAM race regardless of cancer type or tissue of origin.
A complete list of differentially expressed genes in both cohorts is
provided in Supplementary Data 2.
Signaling pathways driving the observed racial differences.
After characterizing genomic and gene expression differences, we
next investigated the extent of differential regulation of key signaling pathways between the EAM and AAM groups. To achieve
this goal, we ﬁrst characterized the activity of cancer hallmark
pathways in the AAM and EAM groups. Pathway activity was
summarized as the mean expression of genes in the pathway. For
every pathway score, we assessed its association with race using
multivariable logistic regression models to calculated associated
P values and odds ratios as described in the “Methods” section.
Results from the multivariable models are shown in Supplementary Data 3. We observed mutual exclusivity in pathways and
overall, AAM group tumors were associated with higher
levels of immune cancer pathways, such as immune response
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Fig. 2 Genome-wide differential expression in AAM and EAM. a Top 22 genes differentially expressed between the two groups in our cohort with
multivariate analysis logistic regression P value <1e−10. Mean difference in TCGA prostate was also shown for these genes to show that these genes show
the same directionality. Genes were sorted based on the mean difference between AAM and EAM. b Boxplot of genes differentially expressed in TCGA
prostate cohort. Abbreviations as in Fig. 1. Error bars represent the 95% conﬁdence interval.

(tumor necrosis factor alpha signaling via NFκB, interferon
alpha, gamma response), apoptosis, hypoxia, and reactive oxygen
species, Fig. 3a (blue bars). In contrast, the EAM group was
associated with higher gene pathway scores for MYC targets,
DNA repair, and WNT-beta-catenin signaling (Fig. 3a, gray bars).
Taken together, our data indicate that key biological processes
associated with cell growth and survival pathways are upregulated
in the EAM group. Our results deﬁne a role for immune signaling
pathways in the AAM group and establish that upregulation of
the immune-inﬂammation axis is a hallmark of AAM tumors.
AAM have higher inﬂammation and immune responses. To
further characterize the biological impact associated with the
upregulation of the immune signaling pathways in AAM, we
conducted Gene Set Enrichment Analysis (GSEA) on genes
upregulated in AAM using the EnrichR web-based tool.
Enrichment signatures revealed signiﬁcant association with the
innate immune system, complement cascade and immunoregulatory interactions (P < 0.001 for all). To further characterize
this association at the gene level, we studied the expression of
several inﬂammation and immune checkpoint inhibitors genes.
Interferon gamma (IFN-G), CCL4, and IL33 were expressed at
higher levels in the AAM group compared with the EAM
group (P < 0.001) (Fig. 3b). The immune biomarker CD3 was
also expressed at signiﬁcantly higher levels in the AAM group
(P < 0.001), as were ICOSLG and PDL2 (Fig. 3b). Our results are
in line with a recent report analyzing pathway activity across
race deﬁned by genetic ancestry in TCGA prostate5. Using
GSEA analysis in this report, the authors identiﬁed 18 gene sets
were upregulated in AAM; 15 of 18 were immune-related signaling pathways. These ﬁndings support the hypothesis that
AAM tumors are both more inﬂamed and more immune active.
AAM have lower DNA repair. Pathway analysis showed that
AAM have lower DNA repair activity. We further investigated
4

other pathways and observed that the AAM group had signiﬁcantly lower mismatch repair activity (Fig. 4a). To further
identify DNA repair genes that are signiﬁcantly driving this difference between the two groups, MSH2, RAD52, MSH6, and
PRKCD were the most strongly downregulated DNA repair genes
in the AAM group (Fig. 4b). MSH2 and MSH6 were also
downregulated in AAM in TCGA prostate (P < 0.001 for both,
Supplementary Fig. 3). Our results indicate that an aberrant DNA
repair activity in AAM could have a signiﬁcant impact on how
AAM tumors respond to radiation therapy. To test this, we used a
previously reported radiation response signature in PCa15 and
found that AAM indeed have higher signature scores (P < 0.0001)
and thus are more likely to respond to radiation therapy. This
observation needs to be tested in radiation therapy clinical trials.
Validation of differential immune response, and immune
response and AR response genes. To further validate the differential expression of nominated targets in AAM vs. EAM on
another platform, we used quantitative PCR to analyze the
transcript proﬁles of representative genes that belong to DNA
repair pathway (MSH2), inﬂammation (CCL3, CCL4, IFNB), and
AR response genes (RLN2, PCGEM1). qPCR ﬁndings conﬁrmed
that genes associated with inﬂammation and AR response are
upregulated in AAM and DNA mismatch repair gene, MSH2 is
downregulated in AAM (Supplementary Figs. 3 and 4).
Transcriptomic heterogeneity of inﬂammation genes in AAM.
To further investigate the role of inﬂammation and immune
genes in tumor progression in AAM, we characterized the
expression of 124 tumor microenvironment and immuneresponse genes in the tumors from these patients. Consensus
unsupervised clustering of AAM patients revealed a cluster of
patients (22% of total AAM patients) who were enriched in
adverse pathology features (deﬁned by GG ≥3 and/or pN+ and/
or pT3–4 disease; 60%) and high genomic risk (53%), and
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Fig. 3 Activation of different signaling pathways drives prostate cancer in AAM and EAM. a The bar plot depicts the log odds of pathways that have a
signiﬁcant association with AAM and EAM after adjusting for clinical variables and false discovery. Many of the pathways more active in the AAM are
related to the immune response. Pathways more active in the EAM include those related to DNA repair, glycolytic metabolism, and the cell cycle. b African
Americans showed higher inﬂammation activity and higher expression of CD3, IFNG, IL33, and immune checkpoint inhibitors (PDL2, ICOSLG). Abbreviations
as in Fig. 1. Error bars represent the 95% conﬁdence interval.

whose tumors had elevated expression of inﬂammation and
immune-response genes, including CD4, CD3, STAT1, GZMA,
IDO1, CD2, CD96, PTPRC (CD45), CCL5, CXCL9, CXCL10, and
CXCL11 (Fig. 5).
Differential response to chemotherapy. To test whether there
was any segregation of chemotherapy sensitivity between the
AAM and EAM, we evaluated predictions for response signatures of seven chemotherapy drugs that were previously
developed using in vitro drug sensitivity and microarray data
from the NCI-60 panel16. For each drug, we used the CellMiner
tool17 to explore NCI-60 data and identify drug responserelated genes and their correlations to the IC50 value of NCI-60
cell lines. The most signiﬁcantly correlated genes were selected
and the expression of the corresponding genes in the Decipher
Genomic Resource Information Database (GRID) were
extracted for drug response score (DRS) calculations. A patientspeciﬁc DRS was calculated using these correlation coefﬁcients
(Cor) as weighting factors of the corresponding gene expression
normalized by the sum of Cor. DRS was generated for 89 drugs
across all 1152 tumor samples. These signatures predicted
AAM men will have higher response score to DNA damage
and alkylating agent-based chemotherapy and EAM men to
potentially respond better to anti-microtubule-based chemotherapy (Supplementary Table 1). These drug response
predictions based on cell lines need to be further investigated in
clinical trials.

Discussion
AAM men are underrepresented in PCa genomic proﬁling
studies. For example, TCGA prostate have only 37 AAM (out of
333 patients). This small size of AAM samples has led to
underpowered studies to identify the meaningful biological
difference and is not enough to capture the heterogeneity in
AAM populations. Thus, there is a need for cohorts enriched
for AAM patients.
This study investigates biological differences between AAM
and EAM is a large transcriptomic cohort with more than 50%
being AAM. This study demonstrated that EAM and AAM
groups have distinct genomic proﬁles, with clinical implications
for managing active surveillance (AS), adjuvant treatment,
recurrence management, and metastatic disease treatment.
Characterizing the clinicopathological variables between AAM
and EAM revealed that being AAM are associated with more
aggressive clinical disease, including higher GGs, CAPRA-S,
and Decipher scores. Observed distinctions in clinical and
molecular characteristics within AAM and EAM can explain
racial disparities in PCa. Our results provide compelling evidence suggesting that AAM considering RP should be carefully
monitored post treatment.
We observed that AAM in our analytical cohort had a higher
genomic risk of metastasis. Decipher and AGR scores correlated
with GG of RP specimens. When stratiﬁed by GGs, AAM patients
with GGs 1 and 2 had higher Decipher scores. In contrast, EAM
patients with GGs 4 and 5 had higher AGR scores. These results
could have clinical implications for AS management of AAM, as
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Fig. 4 Differential expression of DNA repair pathways and genes. a DNA
repair activity and mismatch repair were calculated as mean of genes sets.
Both showed lower activity in African Americans. b Key DNA repair genes
(MSH2, RAD52, and PRKCD) were the most upregulated in patients. Error
bars represent the 95% conﬁdence interval.

AAM are twice as likely (HR, 2, 95% CI, 1.47–2.74, P < 0.0001) to
be reclassiﬁed during AS18 and have a higher genomic risk.
Therefore, careful selection of AS is warranted for AAM men to
avoid the risk of disease progression due to treatment delays.
However, to make a more deﬁnitive recommendation, our
results would need to be validated in an AS cohort. Furthermore,
these results show the likely need for race-adjusted biomarker
development.
An in-depth evaluation of molecular subtypes of PCa between
EAM and AAM showed a signiﬁcant association of SPINK1
expression with AAM tumors. Our ﬁndings are consistent with
previous studies validating that SPINK1 was overexpressed
among AAM19. In addition to SPINK1, we also observed signiﬁcant differences in ERG expression by race. AR-mediated
TMPRSS2-ERG fusion, an early event present in up to 70% of
PCa, has been consistently shown to be absent in AAM10,20.
Consistent with these ﬁndings, we observed that AAM patients
had decreased ERG expression in our study. While the lack of
TMPRSS2-ERG fusion in AAM has been validated, its prognostic
value among AAM remains questionable10,21,22. Nonetheless, our
results are consistent with published literature21,23.
Furthermore, the PAM50 gene expression pattern demonstrated that AAM tumors are more enriched in basal subtypes.
However, luminal B typing was similar between the two races.
Because tumors with luminal B subtypes respond better to
androgen deprivation treatment (ADT)12, a similar expression
proﬁle between EAM and AAM would indicate similar responses
to ADT responses between the groups.
6

Differences in tumor-associated intrinsic or extrinsic factors
can potentially affect their response to drugs. Interestingly, analysis of drug response signatures showed that AAM men are
predicted to have a higher potential response rate to alkylating
agent-based chemotherapy, whereas EAM men have a higher
potential response rate to taxane-based chemotherapy. These
predictions require further validation in data from clinical trials.
Taxane-based chemotherapy is the standard reference treatment
in advanced disease24, which, in theory, can result in favorable
outcomes for EAM in the advanced disease cohort. Although this
idea requires support from clinical outcomes data, it highlights
the need to personalize treatment in patients with biochemical
recurrence. Because alkylating agents work by causing DNA
damage, this observation supports our earlier observation that
AAM show increased susceptibility to DNA-damaging radiation
therapy. If validated, these results could help personalize management of distant recurrence or metastatic disease in AAM.
In contrast, taxane-based chemotherapeutic agents alter the
microtubule network, thereby affecting chromosome segregation
during cell division.
After adjusting for clinical variables and false discovery, we
observed a differential activation of biological pathways in EAM
versus AAM. EAM had higher rates of DNA repair, glycolytic
metabolism, and cell cycle pathway activity, and we also observed
a higher immune response. AAM also had higher inﬂammation
activity, with higher T cell and IFN-γ responses and higher
expression of CD3E, CD3D, ICOSLG, and PDL2. A recent report
has shown that genes upregulated in AAM (ancestry based) in the
TCGA prostate cohort are associated with immune-related signaling pathways5. This study supports our ﬁndings and further
supports the rationale for using immunotherapy in AAM with
PCa. Because novel PCa treatment options include immune
modulation23, understanding these unique racial differences is
likely to understand the speciﬁc immune mechanisms better.
In fact, a subanalysis of the PROCEED trial showed a
surprisingly high survival advantage for AAM receiving immunotherapy for metastatic castration-resistant PCa25. Our data
suggest that AAM tumors have increased inﬂammation and
immune-related functions and could be more responsive to
immunotherapy regimens. Accordingly, we identiﬁed a subset of
AAM tumors with molecular features that are likely to be more
responsive to immunotherapy.
Our results could explain the underlying molecular mechanism
of the differential response to radiotherapy and possible differences in outcome among AAM. Emerging studies have demonstrated that lower DNA repair is a prominent molecular feature of
low AR activity which is linked with poor disease prognosis and
response of radiotherapy26,27. Consequently, lower DNA repair
activity can also underscore the molecular basis of higher radiation response among AAM with high-risk PCa28. Our ﬁndings
are consistent with the meta-analysis of the RTOG trial that
showed that AAM had better responses to radiation therapy due
to differential AR signaling and DNA repair activity26. Although,
we studied a RP cohort, we can extrapolate that gene signature
and commercially available genomic test can individualize adjuvant treatment selection among AAM29. Further work in this
regard is warranted.
The limitations of our study lie in its retrospective design and
the inherent selection bias. Furthermore, our results are mostly
descriptive, and we lack the data and sufﬁcient follow-up to
analyze oncological outcomes. The RNA expression data were
derived from Decipher testing based on clinical indications; thus,
our study represents a higher-risk cohort than the standard RP
population. Therefore, our analytical cohort represents an
ideal population in which to make assumptions regarding adjuvant or systemic treatment in the metastatic setting. Caution is
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Fig. 5 Tumor inﬂammation heterogeneity in AAM. Using a set of 124 inﬂammation and immune-response genes in AAM, consensus clustering revealed a
cluster of patients with high expression of immune genes (CD3, CD45, GZMA, B2M, STAT1), nominating this cluster for immunotherapy treatment
intervention. AAM African-American men, APF adverse pathology feature.

recommended when applying clinical setting results to predict
response to systemic therapy since patients were already treated
with RP. Furthermore, unmeasured confounding resulting from
socioeconomic factors can contribute to the baseline differences
between the two races30, and, therefore may impact the validity of
our results. Regardless, this AAM-enriched cohort represents one
of the largest multi-institutional analytical cohorts with complete
molecular information to understand the distinct biologic features within race groups. In addition, a large sample size, along
with extensive clinico-pathologic and genomic information,
supports the strength and reproducibility of our results.
In conclusion, signiﬁcant biological differences in PCa appear
to depend, in part, on a man’s racial ancestry, as well as, potentially his psychosocial and cultural environment. The inclusion of
data from other racial groups will help further our understanding
of the observed clinical heterogeneity of PCa and may have
implications for personalized treatment in the future.
Methods
Data source and eligibility. We performed an Institutional Review Boardapproved (Icahn School of Medicine at Mount Sinai) retrospective analysis of deidentiﬁed genome-wide expression proﬁles in the GRID registry (NCT02609269)
from clinical use of the Decipher Prostate RP test (Decipher Biosciences, San
Diego, California). Expression data for each patient included the clinical Decipher
score, as well as 20 pre-computed gene expression prognostic signatures and 56
hallmarks of cancer pathway activity scores, and genome-wide expression proﬁles
using more than 46,000 gene and noncoding genes31. None of these patients
received radiotherapy and/or androgen deprivation therapy before molecular
testing. Overall, 1152 patients (596 AAM and 556 EAM) with available data on race
and gene expression were included in this analysis.

Clinical and pathology data. Baseline demographic and clinical data included age,
physician-reported patient race, and pretreatment PSA levels. Other pathologic
variables, such as GG, pathological T (pT) stage and pathological N (pN) stage
were also included. GGs were categorized based on the 2014 International Society
of Urological Pathology Consensus Conference adopted GGs32. The CAPRA-S
score was calculated as previously described33. Finally, patients genomic-risk
classiﬁer, Decipher score, was also used34.
Specimen collection and RNA expression proﬁling. From RP specimens,
formalin-ﬁxed parafﬁn-embedded blocks were submitted for Decipher testing.
Submitted tumor tissue included the highest GG with at least 0.5 mm2 of tissue.
RNA was extracted using the RNeasy kit (Qiagen, Santa Clara, California), and
cDNA was prepared and ampliﬁed using the NuGEN Ovation WTA assay and
hybridized to Human Exon 1.0 ST microarrays (Thermo-Fisher, Carlsbad, California), as described previously34. Microarray quality control was performed using
Affymetrix Power Tools, as described previously35. Finally, probe-set summarization and normalization were performed using the single-channel array normalization algorithm36, and the Decipher score was calculated as previously
described34.
For external validation of nominated targets in other platform qPCR, RNA
isolated from fresh primary PCa tissues obtained from EAM and AAM (n = 11)
who consented to PPHS/IRB study (Mount Sinai # GCO 14-0318) were used. Total
RNA was prepared using Purelink RNA mini kit (Invitrogen) and reverse
transcribed using the iscript Advanced cDNA synthesis reagent’s following the
manufacturer’s instructions (BioRad Laboratories, USA). Tissues were
homogenized in lysis buffer to ensure RNAse-free lysis and puriﬁed through a mini
spin column. Following multiple washes, total RNA was collected into a ﬁnal
volume of 30 µl. Total RNA was measured using nano-drop and 260/230 and 260/
280 ratios were considered as measure of quality. Quantitative real-time PCR was
performed using SSO-Advanced Universal SYBR Green supermix (BioRad
Laboratories, USA) and was analyzed on the CFX384 Touch real-time PCR system
(BioRad Laboratories). Transcript levels were measured using the Delta-Ct method
after normalization to seven housekeeping genes (ACTB, HMBS, RPL38, TBP,
GAPDH, HPRT, PSMC1)37,38.
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Pathway activity calculation and gene set enrichment analysis. Pathway
activity scores were calculated for hallmarks of cancer pathways (Supplementary
Data 1) from the Molecular Signatures Database39. After scaling the expression
of genes within each pathway gene set, the average of the scaled expression was
used to represent pathway activity score as previously described40. An adjustment was made for baseline clinical differences between the two races using
multivariable logistic regression. Finally, GSEA was conducted using the
EnrichR online tool41.
Statistical analysis. Analyses of the associations between categorical variables
were conducted using the chi-square test or Fisher exact tests. The Mann–Whitney
U test was used as to evaluate the difference between non-normally distributed
continuous variables. Multivariable logistic regression analysis adjusting for GG,
pT stage and lymph node involvement was used to predict race (binary response
variable) from hallmarks pathway activity scores (continuous predictor variable).
Logistic regression here was applied for every pathway/gene individually to ﬁnd a
statistical association between race and pathway activity or gene expression using
the following formula:
“log (p/1 − p) (p = 1: AAM, 0: EAM) = β0 + β1 x pathway + β2 x Gleason + β3
x EPE + β4 x SVI + β5 x LNI + ε”, where log (p/1 − p) is a logit function and ε is
an error for logistic regression formula. Then, the P value and odds ratio of β1 was
evaluated for all pathways. P values of multiple comparisons across pathways were
controlled for FDR using the Benjamini–Hochberg procedure.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.

Data availability
Gene expression data used in this study are available upon request from the PI of this
study (A.K.T.). Gene expression data are also freely available from the Decipher GRID
upon request from Decipher Biosciences Inc. The microarray data that support the
ﬁndings of this study were deposited on NCBI Gene expression Omnibus (GEO) and are
accessible through GEO accession number GSE169038. Source data for Fig. 2 are
available in Supplementary Data 4. A subanalysis of our work is in part based upon data
generated by the TCGA Research Network: https://www.cancer.gov/tcga.

Code availability
R Codes used in this study are created by M.A. and codes are available to be shared based
on request. Metadata and R code used to generate the ﬁgures is available in
Supplementary Data 5.
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